

**PERIPHERAL ARTERY DISEASE
UNITED STATES ENDOVASCULAR PROCEDURE MARKET
BY DISEASE SEVERITY AND VASCULAR TERRITORY
AORTOILIAC, FEMOROPOPLITEAL AND INFRAPOPLITEAL
2015-2040**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2024

All rights reserved, including the right of reproduction
in whole or in part in any form.

REFERENCES

REFERENCES (FIRST AND LAST PAGES)

1. Yost ML. The Current U.S. Prevalence of Peripheral Arterial Disease. *Vascular Disease Management*. 2023;20(4):E67-E73.
2. Yost ML. Critical Limb Ischemia Volume I. *United States epidemiology*. 2016 Supplement. Beaufort (SC):THE SAGE GROUP;2016.
3. Yost ML. Critical limb ischemia. Volume I. *United States epidemiology*. Atlanta (GA): THE SAGE GROUP; 2010.
4. U.S. Census Bureau. Projected Age Groups and Sex Composition of the Population: Main Projections Series for the United States, 2017-2060. Table 2. U.S. Census Bureau, Population Division: Washington, DC. 2017.
5. U.S. Census Bureau. Population Projections Program, Population Division. Table 12. Projections of the Population by Age and Sex for the United States: 2010 to 2050 (NP2008-T12) 2008, Aug 14.
6. Yost ML. Peripheral artery disease by disease severity. Estimates of intermittent claudication, critical limb ischemia and asymptomatic/atypical disease 2015-2040. THE SAGE GROUP;2024. Unpublished.
7. Yost ML. Peripheral arterial disease. Volume II. Atlanta (GA):THE SAGE GROUP; 2004.
8. Baumgartner I, Norgren L, Fowkes FGR, et al; Executive Committee and Investigators of the EUCLID Trial. Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID Trial. *J Am Coll Cardiol*. 2018 Oct 2;72(14):1563-1572.
9. Yost ML. Peripheral artery disease. Interventional market analysis based on treatment with angioplasty or atherectomy. Atlanta (GA):THE SAGE GROUP; 2012.
10. Anantha-Narayanan M, Doshi RP, Patel K, et al. Contemporary trends in hospital admissions and outcomes in patients with critical limb ischemia: an analysis from the National Inpatient Sample Database. *Circ Cardiovasc Qual Outcomes*. 2021 Feb; 14(2):e007539.
11. Agarwal S, Sud K, Shishehbor MH. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients: From 2003-2011. *J Am Coll Cardiol*. 2016 Apr 26;67(16):1901-13.
12. Mustapha JA, Katzen BT, Neville RF, et al. Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study. *J Am Heart Assoc*. 2018 Aug 21;7(16):e009724.

74. Mouawad NJ, Woo K, Malgor RD, et al. The impact of the COVID-19 pandemic on vascular surgery practice in the United States. *J Vasc Surg.* 2021 Mar;73(3):772-779.e4.
75. Lou JY, Kennedy KF, Menard MT, et al. North American lower-extremity revascularization and amputation during COVID-19: Observations from the Vascular Quality Initiative. *Vasc Med.* 2021 Dec;26(6):613-623.
76. Zil E Ali A, D'Addario J, Smeds M, et al. Impact of COVID-19 on the endovascular and open surgical management of peripheral arterial disease and aortic aneurysmal disease – an analysis of the VQI Database. *J Vasc Surg.* 2021 Sep;74(3):e263–6.
77. Lal BK, Prasad N, Englum B, et al. National impact of COVID-19 on vascular surgery services. *J Vasc Surg.* 2021 Sep;74(3):e71.
78. Miranda JA, Chung J, Mills JL. Influence of the COVID-19 pandemic on the management of chronic limb-threatening ischemia. *Semin Vasc Surg.* 2021 Sep;34(3):89-95.
79. Lancaster EM, Wu B, Iannuzzi J, Oskowitz A, et al. Impact of the coronavirus disease 2019 pandemic on an academic vascular practice and a multidisciplinary limb preservation program. *J Vasc Surg.* 2020 Dec;72(6):1850-1855.

CONTACT INFORMATION

Mary L. Yost

Telephone (404) 520-6652

yost@thesagegroup.us